Enhanced Group Commends FDA Committee’s Recommendation On Peptides, Sees Major Step Toward Closing Gray Market And Advancing Regulatory Pathway

Committee’s Recommendation on BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax Marks a Major Step Toward Closing the Gray Market

Enhanced Positioned to Benefit as the Regulatory Pathway Advances

Enhanced Group Inc. (NYSE:ENHA) the elite sports competition and personalized performance products company commended the United States Food & Drug Administration’s (FDA) Pharmacy Compounding Advisory Committee (PCAC) for its vote last week recommending that BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax be added to the FDA's Section 503A Bulk Drug Substances List. This recommendation is a critical step toward providing licensed U.S. compounding pharmacies a legal, regulated pathway to prepare these peptides for consumers, many of whom currently secure these substances via unregulated providers.